Key Patent Issues Covering Protagonist Therapeutics' Oral Peptide IL-23 Receptor Antagonists, including the Development Candidate PTG-200
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: PR Newswire
MILPITAS, Calif., May 4, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that a key patent has issued covering orally stable peptide inhibitors of the interleukin-23 receptor (IL-23R), including the company's clinical development candidate, PTG-200. The new U.S. patent, No. 9,624,268, provides composition of matter protection for PTG-200 and covers the use of the oral peptide inhibitors of IL-23R to treat inflammatory bowel diseases (IBD). "This new patent provides intellectual property coverage until 2035 for our orally stable IL-23 receptor peptide inhibitors, including PTG-200," said David Liu, Ph.D., Protagonist's Chief Scientific Officer and Head of R&D. "Inhibition of the IL-23 pathway is an effective therapeutic treatment for IBD, as evidenced by a marketed injectable antibody drug for treatment of Crohn's disease. PTG-200 is an oral IL-23R antagonist and is designed to offer potential advantages such as improved conveni
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Turnstone Biologics Appoints William Waddill to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Hemochromatosis Pipeline Insight Report 2024, Featuring Protagonist Therapeutics, Sirnaomics and Bond Biosciences [Yahoo! Finance]Yahoo! Finance
- Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135% [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataAccesswire
PTGX
Earnings
- 8/3/23 - Miss
PTGX
Sec Filings
- 4/19/24 - Form 4
- 4/12/24 - Form PRE
- 4/2/24 - Form 4
- PTGX's page on the SEC website